
High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum
Keywords: Peritoneal carcinomatosis; Intraperitoneal radioimmunotherapy; Fab; IgG; IgM radioimmunoconjugates; Gamma-emitter 111In; Alpha-emitter 213Bi; Peritoneal retention